Inclusion Criteria:  Subjects must meet all of the following Inclusion Criteria:  18 years or older at the time of the scheduled TAVR ViV treatment Currently has an INSPIRIS RESILIA aortic valve implanted in the aortic position confirmed to be size 19mm, 21mm, 23mm or 25mm An in situ INSPIRIS RESILIA aortic valve is determined to be experiencing valve dysfunction for which Valve-in-Valve (ViV) treatment is indicated A ViV procedure using an Edwards transcatheter aortic heart valve (TAVR) FDA-approved for ViV has been scheduled The participant agrees to attend all follow-up assessments for up to 3 months post ViV procedure The participant provides written informed consent  Exclusion Criteria:  Subjects must not meet any of the following Exclusion Criteria:  The INSPIRIS RESILIA aortic valve size is  Unconfirmed, or Confirmed to be 27mm or 29mm Prior re-interventions have been performed on the INSPIRIS RESILIA aortic valve The INSPIRIS RESILIA aortic valve has been subjected to balloon aortic valvuloplasty (BAV) prior to the baseline quantitative area measurement of the valve area The Subject is pregnant or desires to become pregnant within 120 days of the ViV procedure Subjects with a known contraindication or hypersensitivity to contrast media that cannot be adequately pre-medicated per hospital guidelines